Cordance Medical has closed an oversubscribed seed round that blasted past its $8 million target, the med-tech company has announced. This marks a major vote of confidence in its noninvasive focused-ultrasound platform designed to open the blood-brain barrier.

 

The round was led by Sonder Capital and drew a mix of returning and new backers, including Shanda Grab Ventures, Angel Physician's Fund, SmartGateVC, and R42. Also joining were two heavyweight neuro-oncology investors—the Sontag Foundation Innovation Fund and the Brain Tumor Investment Fund—underscoring growing momentum behind technologies that could reshape brain-cancer care.

 

The fresh capital will propel Cordance into its first-in-human clinical trial, testing a system built to safely and temporarily open the blood-brain barrier to help therapies reach the brain more effectively. If successful, the technology could broaden treatment possibilities for patients with brain cancer and other neurological diseases that remain notoriously hard to treat.

 

Cordance’s platform is engineered for outpatient use, relying on patient-specific signal processing and real-time monitoring of blood-brain-barrier opening—without the need for head fixation or live imaging. The company already holds FDA Breakthrough Device Designation in neuro-oncology and recently secured a National Cancer Institute grant to support its upcoming US trial.

 

"Our team is thrilled to announce this financing round and is grateful to all our investors for their confidence in our mission," said Bhaskar Ramamurthy, Co-founder and CEO of Cordance Medical. "Alongside our academic collaborators and industry partners, this strong syndicate backing reflects the urgent need for precision therapies in neurology, where patients face extremely limited treatment options. Combined with NIH support for our first-in-human trial, this funding accelerates our path to delivering transformative care."

 

"Focused ultrasound continues to revolutionize treatment across multiple therapeutic areas," said Deborah Kilpatrick, Partner at Sonder Capital. "We believe that Cordance has the potential to establish new standards of care in neurology with a platform purpose-built for practical, outpatient delivery of BBB-mediated therapies for both pediatric and adult patients."